How the Landscape Around DCTs is Changing
Innovations in clinical trials are needed to significantly impact and improve key pain points in operational execution. Improvements in technologies and methods to drive clinical trial innovations have focused on the incorporation of decentralized clinical trials (DCTs)—also sometimes referred to as “remote,” “hybrid,” “virtual,” or “patient-centric” trials. The COVID-19 pandemic has significantly accelerated the adoption of DCTs, which allowed sponsors and CROs to quickly virtualize many trial activities. The uptake in DCTs is expected to continue in a post-COVID-19 world due to the experience gained during the pandemic.
This white paper outlines the changing landscape around DCTs with new types of solutions, regulatory challenges, and acceptances and ongoing discussions around running decentralized clinical trials.
Offered Free by: Medidata
See All Resources from: Medidata
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.